For research and educational purposes only. Not medical advice.
Orforglipron Reference
Educational, not medical advice reference for Orforglipron: GLP-1, Fat Loss; regulatory status, evidence posture, source review, and schedule notes. Also kno…
Reference summary
Phase 3 trial data have been reported by Lilly, but orforglipron is not FDA-approved. pepSmart displays orforglipron only as trial-context educational content.
- Categories
- GLP-1, Fat Loss
- Aliases
- LY3502970, Oral non-peptide GLP-1 agonist
- Evidence posture
- human — Large Phase 3 data exist, but orforglipron remains investigational.
- Regulatory status
- Investigational. Orforglipron is an oral non-peptide small-molecule GLP-1 receptor agonist in Lilly's Phase 3 program (ACHIEVE diabetes, ATTAIN obesity). There is no FDA-approved orforglipron drug label.
- Content review status
- investigational verified